JPWO2020117564A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020117564A5 JPWO2020117564A5 JP2021531637A JP2021531637A JPWO2020117564A5 JP WO2020117564 A5 JPWO2020117564 A5 JP WO2020117564A5 JP 2021531637 A JP2021531637 A JP 2021531637A JP 2021531637 A JP2021531637 A JP 2021531637A JP WO2020117564 A5 JPWO2020117564 A5 JP WO2020117564A5
- Authority
- JP
- Japan
- Prior art keywords
- site
- skin
- drug
- microneedle
- microneedles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 97
- 229940079593 drugs Drugs 0.000 claims description 97
- 239000000203 mixture Substances 0.000 claims description 86
- 210000003491 Skin Anatomy 0.000 claims description 38
- 108090001123 antibodies Proteins 0.000 claims description 38
- 102000004965 antibodies Human genes 0.000 claims description 38
- 239000000839 emulsion Substances 0.000 claims description 24
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 18
- 208000002193 Pain Diseases 0.000 claims description 15
- 230000003750 conditioning Effects 0.000 claims description 14
- 231100000344 non-irritating Toxicity 0.000 claims description 13
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 12
- 230000001815 facial Effects 0.000 claims description 12
- 239000003961 penetration enhancing agent Substances 0.000 claims description 12
- 230000037303 wrinkles Effects 0.000 claims description 12
- 210000003205 Muscles Anatomy 0.000 claims description 9
- 108010043024 Botulinum Toxins Proteins 0.000 claims description 8
- 239000004907 Macro-emulsion Substances 0.000 claims description 8
- 229940053031 botulinum toxin Drugs 0.000 claims description 8
- 239000000969 carrier Substances 0.000 claims description 8
- 239000007908 nanoemulsion Substances 0.000 claims description 8
- 239000000560 biocompatible material Substances 0.000 claims description 7
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 7
- 206010002023 Amyloidosis Diseases 0.000 claims description 6
- 206010002022 Amyloidosis Diseases 0.000 claims description 6
- 229940088623 Biologically Active Substance Drugs 0.000 claims description 6
- 206010055000 Bromhidrosis Diseases 0.000 claims description 6
- 229940012356 Eye Drops Drugs 0.000 claims description 6
- 206010019233 Headache Diseases 0.000 claims description 6
- 229940040145 Liniment Drugs 0.000 claims description 6
- 208000009856 Lung Disease Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims description 6
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims description 6
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 6
- 208000006641 Skin Disease Diseases 0.000 claims description 6
- 206010040904 Skin odour abnormal Diseases 0.000 claims description 6
- 201000004384 alopecia Diseases 0.000 claims description 6
- 230000037371 chromhidrosis Effects 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000003889 eye drop Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 230000003676 hair loss Effects 0.000 claims description 6
- 231100000869 headache Toxicity 0.000 claims description 6
- 230000037315 hyperhidrosis Effects 0.000 claims description 6
- 239000000865 liniment Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 201000001263 psoriatic arthritis Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 230000035900 sweating Effects 0.000 claims description 6
- 210000004207 Dermis Anatomy 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 210000000434 stratum corneum Anatomy 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 4
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 3
- 229940035674 ANESTHETICS Drugs 0.000 claims description 3
- 206010000496 Acne Diseases 0.000 claims description 3
- 208000009621 Actinic Keratosis Diseases 0.000 claims description 3
- 108010007562 Adalimumab Proteins 0.000 claims description 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 3
- 206010003246 Arthritis Diseases 0.000 claims description 3
- 208000006673 Asthma Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 108010070202 Certolizumab Pegol Proteins 0.000 claims description 3
- 241000193163 Clostridioides difficile Species 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010011401 Crohn's disease Diseases 0.000 claims description 3
- 206010011659 Cutaneous amyloidosis Diseases 0.000 claims description 3
- 206010058108 Dyslipidaemia Diseases 0.000 claims description 3
- 208000010118 Dystonia Diseases 0.000 claims description 3
- 208000005679 Eczema Diseases 0.000 claims description 3
- 108010008165 Etanercept Proteins 0.000 claims description 3
- 229950010512 Fezakinumab Drugs 0.000 claims description 3
- 229950010864 Guselkumab Drugs 0.000 claims description 3
- 210000003780 Hair Follicle Anatomy 0.000 claims description 3
- 208000004095 Hemifacial Spasm Diseases 0.000 claims description 3
- 208000009576 Hypercholesterolemia Diseases 0.000 claims description 3
- 206010020713 Hyperpigmentation disease Diseases 0.000 claims description 3
- 206010021064 Hypopigmentation disease Diseases 0.000 claims description 3
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 3
- 108010053490 Infliximab Proteins 0.000 claims description 3
- 206010061227 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000008085 Migraine Disorders Diseases 0.000 claims description 3
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 3
- 206010062575 Muscle contracture Diseases 0.000 claims description 3
- 206010028334 Muscle spasms Diseases 0.000 claims description 3
- 208000006883 Neuromuscular Disease Diseases 0.000 claims description 3
- 206010061536 Parkinson's disease Diseases 0.000 claims description 3
- 241000223503 Platysma Species 0.000 claims description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
- 208000003782 Raynaud Disease Diseases 0.000 claims description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 3
- 241001303601 Rosacea Species 0.000 claims description 3
- 210000001732 Sebaceous Glands Anatomy 0.000 claims description 3
- 210000002374 Sebum Anatomy 0.000 claims description 3
- 229960004540 Secukinumab Drugs 0.000 claims description 3
- 229950003804 Siplizumab Drugs 0.000 claims description 3
- 206010040872 Skin infection Diseases 0.000 claims description 3
- 208000005392 Spasm Diseases 0.000 claims description 3
- 208000004350 Strabismus Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 210000000106 Sweat Glands Anatomy 0.000 claims description 3
- 206010044565 Tremor Diseases 0.000 claims description 3
- 108010077389 Ustekinumab Proteins 0.000 claims description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 229950009002 Zanolimumab Drugs 0.000 claims description 3
- 229960002964 adalimumab Drugs 0.000 claims description 3
- 230000003444 anaesthetic Effects 0.000 claims description 3
- 108010034406 briakinumab Proteins 0.000 claims description 3
- 229960002874 briakinumab Drugs 0.000 claims description 3
- 108010011709 brodalumab Proteins 0.000 claims description 3
- 229960003735 brodalumab Drugs 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 229960003115 certolizumab pegol Drugs 0.000 claims description 3
- 230000001684 chronic Effects 0.000 claims description 3
- 229960005188 collagen Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229960000403 etanercept Drugs 0.000 claims description 3
- -1 etanercept-szzs Proteins 0.000 claims description 3
- 108010062604 fezakinumab Proteins 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 229960001743 golimumab Drugs 0.000 claims description 3
- 108010086781 golimumab Proteins 0.000 claims description 3
- 108010020157 guselkumab Proteins 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 229960000598 infliximab Drugs 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000000926 neurological Effects 0.000 claims description 3
- 230000000414 obstructive Effects 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 201000004681 psoriasis Diseases 0.000 claims description 3
- 201000004700 rosacea Diseases 0.000 claims description 3
- 108010040425 secukinumab Proteins 0.000 claims description 3
- 108010073705 siplizumab Proteins 0.000 claims description 3
- 201000006704 ulcerative colitis Diseases 0.000 claims description 3
- 229960003824 ustekinumab Drugs 0.000 claims description 3
- 108010052251 zanolimumab Proteins 0.000 claims description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 1
- 206010063006 Facial spasm Diseases 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 230000001660 hyperkinetic Effects 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 210000004271 bone marrow stromal cells Anatomy 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 206010020651 Hyperkinesia Diseases 0.000 description 2
- 208000000269 Hyperkinesis Diseases 0.000 description 2
- 206010041925 Staphylococcal infection Diseases 0.000 description 2
- 230000001143 conditioned Effects 0.000 description 2
- 125000000017 cortisol group Chemical group 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 125000002345 steroid group Chemical group 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774677P | 2018-12-03 | 2018-12-03 | |
| US62/774,677 | 2018-12-03 | ||
| US201962789407P | 2019-01-07 | 2019-01-07 | |
| US62/789,407 | 2019-01-07 | ||
| US201962808274P | 2019-02-20 | 2019-02-20 | |
| US62/808,274 | 2019-02-20 | ||
| PCT/US2019/063351 WO2020117564A1 (en) | 2018-12-03 | 2019-11-26 | Improved delivery of large agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510007A JP2022510007A (ja) | 2022-01-25 |
| JPWO2020117564A5 true JPWO2020117564A5 (ko) | 2022-12-05 |
Family
ID=68966029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531637A Pending JP2022510007A (ja) | 2018-12-03 | 2019-11-26 | 大型薬物の送達改善 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220031595A1 (ko) |
| EP (1) | EP3890704A1 (ko) |
| JP (1) | JP2022510007A (ko) |
| KR (1) | KR20210102301A (ko) |
| CN (1) | CN113423381A (ko) |
| AU (1) | AU2019391791A1 (ko) |
| BR (2) | BR122023023068A2 (ko) |
| CA (1) | CA3119043A1 (ko) |
| IL (1) | IL283627A (ko) |
| MX (1) | MX2021006102A (ko) |
| SG (1) | SG11202104838SA (ko) |
| WO (1) | WO2020117564A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| KR20230024669A (ko) * | 2021-08-12 | 2023-02-21 | 주식회사 페로카 | 마이크로니들 패치 |
| CN114191376B (zh) * | 2022-01-05 | 2024-03-01 | 中国药科大学 | 一种用于治疗阿尔兹海默症的微针贴片及其制备方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US7384918B2 (en) | 1991-09-24 | 2008-06-10 | Allergan, Inc. | Botulinum toxin for treating muscle contracture |
| US6939852B2 (en) | 1991-09-24 | 2005-09-06 | Allergan, Inc. | Methods and compositions for the treatment of cerebral palsy |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| ZA200707351B (en) | 2005-03-03 | 2010-02-24 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
| CA2642182A1 (en) * | 2006-02-17 | 2007-08-30 | Zogenix, Inc. | Method and system for delivery of neurotoxins |
| WO2008039245A2 (en) | 2006-04-27 | 2008-04-03 | Anterios, Inc. | Assessment of the effects of topical administration of chemodenervating pharmaceuticals |
| US20120150023A1 (en) | 2007-08-06 | 2012-06-14 | Kaspar Roger L | Microneedle arrays for active agent delivery |
| CN105147608B (zh) * | 2008-06-26 | 2019-12-10 | 安特里奥公司 | 真皮递送 |
| WO2010056922A2 (en) * | 2008-11-12 | 2010-05-20 | Kythera Biopharmaceuticals, Inc. | Systems and methods for delivery of biologically active agents |
| KR102005930B1 (ko) | 2008-12-31 | 2019-07-31 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
| HUE051711T2 (hu) * | 2010-06-01 | 2021-03-29 | Seqirus Uk Ltd | Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül |
| TR201905477T4 (tr) | 2011-01-24 | 2019-05-21 | Anterios Inc | Nano-parçacık bileşimler. |
| EP3689331A1 (en) | 2011-01-24 | 2020-08-05 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses thereof |
| EP2793869B1 (en) | 2011-12-21 | 2015-09-23 | 3M Innovative Properties Company | Transdermal adhesive patch assembly with removable microneedle array and method of using same |
| US20170209553A1 (en) * | 2016-01-22 | 2017-07-27 | Transderm, Inc. | Delivery of botulinum with microneedle arrays |
| US11311496B2 (en) * | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| CN107320841A (zh) * | 2017-08-03 | 2017-11-07 | 党明 | 一种高分子微针及其制备方法和应用 |
-
2019
- 2019-11-26 US US17/297,493 patent/US20220031595A1/en active Pending
- 2019-11-26 AU AU2019391791A patent/AU2019391791A1/en active Pending
- 2019-11-26 JP JP2021531637A patent/JP2022510007A/ja active Pending
- 2019-11-26 EP EP19824093.9A patent/EP3890704A1/en active Pending
- 2019-11-26 MX MX2021006102A patent/MX2021006102A/es unknown
- 2019-11-26 KR KR1020217020839A patent/KR20210102301A/ko unknown
- 2019-11-26 BR BR122023023068-0A patent/BR122023023068A2/pt unknown
- 2019-11-26 WO PCT/US2019/063351 patent/WO2020117564A1/en unknown
- 2019-11-26 SG SG11202104838SA patent/SG11202104838SA/en unknown
- 2019-11-26 CA CA3119043A patent/CA3119043A1/en active Pending
- 2019-11-26 CN CN201980091096.8A patent/CN113423381A/zh active Pending
- 2019-11-26 BR BR112021009554-3A patent/BR112021009554A2/pt unknown
-
2021
- 2021-06-01 IL IL283627A patent/IL283627A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535829A5 (ko) | ||
| DE60104686T2 (de) | Applikator mit auf einer schleiffende oberfläche überzogene substanz zum auftragen auf haut | |
| US20220218623A1 (en) | Transdermal delivery of large agents | |
| US7507419B2 (en) | Topically applied Clostridium botulinum toxin compositions and treatment methods | |
| JP2016117765A5 (ko) | ||
| US20120029261A1 (en) | Systems and methods for delivery of a therapeutic agent | |
| JP6046609B2 (ja) | 皮膚ケア製品の送達 | |
| JP2014503587A (ja) | 界面活性剤組成物 | |
| JP2011519638A (ja) | 経皮拡散促進のための方法および装置 | |
| US5883135A (en) | Composition, device, and method for enhanced electrotransport agent delivery | |
| JPWO2020117564A5 (ko) | ||
| US20220031595A1 (en) | Improved delivery of large agents | |
| JPWO2018093465A5 (ko) | ||
| Oziomek et al. | Effect of phonophoresis on serum salicylate levels | |
| US20220296503A1 (en) | Delaying peak effect and/or extending duration of response | |
| JPWO2020231983A5 (ko) | ||
| DE10103158A1 (de) | Vorrichtung zur elektrisch unterstützen Abgabe von Wirkstoffen aus flächenförmigen therapeutischen Systemen | |
| Guy | Transdermal science and technology-an update | |
| Vaseem et al. | Transdermal Drug Delivery Systems: A Focused Review of the Physical Methods of Permeation Enhancement | |
| Lebwohl et al. | Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials | |
| Indermun | Pharma-engineering of multifunctional microneedle array device for application in chronic pain | |
| Desai | Transdermal Delivery Of Human Growth Hormone. | |
| Wang et al. | Transdermal Drug Delivery Technology |